Download HIV Resistance Publications - May to July/August 2009

HIV Resistance Publications - May to July/August 2009
Title
Author
Abstracts Presented at the XVIII
International HIV Drug Resistance
Workshop
Journal
Volume
Issue
June 2009, Florida
Genetic determinants in HIV-1 Gag and
Env V3 are related to viral response to
combination antiretroviral therapy with a
protease inhibitor.
Ho SK
AIDS - Epub ahead
of print
The dynamics of appearance and
disappearance of HIV-1 integrase
mutations during and after withdrawal of
raltegravir therapy.
Ferns RB
AIDS - Epub ahead
of print
Nucleoside reverse transcriptase
inhibitor-sparing regimen (nonnucleoside
reverse transcriptase inhibitor + protease
inhibitor) was more likely associated with
resistance comparing to nonnucleoside
reverse transcriptase inhibitor or
protease inhibitor + nucleoside reverse
transcriptase inhibitor in the randomized
ANRS 121 trial
Soulié, Cathia
AIDS - July 2009
23
12
Additional HIV-1 mutation patterns
associated with reduced phenotypic
susceptibility to etravirine in clinical
samples
Kagan, Ron M
AIDS - July 2009
23
12
The impact of transmission clusters on
primary drug resistance in newly
diagnosed HIV-1 infection
Yerly, Sabine
AIDS - July 2009
23
11
Detection of low-frequency pretherapy
chemokine (CXC motif) receptor 4
(CXCR4)-using HIV-1 with ultra-deep
pyrosequencing
Archer, John
AIDS - June 2009
23
10
The public health approach to identify
antiretroviral therapy failure: high-level
nucleoside reverse transcriptase inhibitor
resistance among Malawians failing firstline antiretroviral therapy
Hosseinipour, Mina C
AIDS - June 2009
23
9
Antiretroviral medication adherence and
the development of class-specific
antiretroviral resistance
Gardner, Edward M
AIDS - June 2009
23
9
Increased mutations in Env and Pol
suggest greater HIV-1 replication in
sputum-derived viruses compared with
blood-derived viruses
Wagner, Thor A
AIDS - May 2009
23
8
Women exposed to single-dose
nevirapine in successive pregnancies:
effectiveness and nonnucleoside reverse
transcriptase inhibitor resistance
McIntyre, James A
AIDS - April 2009
23
7
Antiretroviral drug susceptibility among
drug-naive adults with recent HIV
infection in Rakai, Uganda
Eshleman, Susan H
AIDS - April 2009
23
7
Tolerance and viral resistance after
single-dose nevirapine with tenofovir and
emtricitabine to prevent vertical
transmission of HIV-1
The TEmAA ANRS
12109 Study group
AIDS - April 2009
23
7
Comparison of Laboratory Methods for
Analysis of Non-nucleoside Reverse
Transcriptase Inhibitor Resistance in
Ugandan Infants
Jessica D. Church
Aids Research and
Human
Retroviruses - July
2009
25
7
Pol Bootscanning Analysis of HIV Type 1
Can Exhibit Unexpected Recombinations
Anne-Cécile Jeannot
Aids Research and
Human
Retroviruses - July
2009
25
7
Analysis of HIV Type 1 gp41 and
Enfuvirtide Susceptibility among Men in
the United States Who Were HIV Infected
Prior to Availability of HIV Entry Inhibitors
Sarah E. Hudelson
Aids Research and
Human
Retroviruses - July
2009
25
7
Comparison of HIV Type 1 Sequences
from Plasma, Cell-Free Breast Milk, and
Cell-Associated Breast Milk Viral
Populations in Treated and Untreated
Women in Mozambique
Mauro Andreotti
Aids Research and
Human
Retroviruses - July
2009
25
7
Characterization of Genetically Diverse
HIV Type 1 from a London Cohort: Near
Full-Length Genomic Analysis of a
Subtype H Strain
Vera Holzmayer
Aids Research and
Human
Retroviruses - July
2009
25
7
Modulation of K65R Selection by
Zidovudine Inclusion: Analysis of HIV
Resistance Selection in Subjects with
Virologic Failure Receiving Once-Daily
Abacavir/Lamivudine/Zidovudine and
Tenofovir DF (Study COL40263)
Lisa Ross
Aids Research and
Human
Retroviruses - July
2009
25
7
In Utero HIV Infection Is Associated with
an Increased Risk of Nevirapine
Resistance in Ugandan Infants Who Were
Exposed to Perinatal Single Dose
Nevirapine
Jessica D. Church
Aids Research and
Human
Retroviruses - July
2009
25
7
Current HIV Type 1 Molecular
Epidemiology Profile and Identification of
Unique Recombinant Forms in Jakarta,
Indonesia
Ivo N. Sahbandar
Aids Research and
Human
Retroviruses - July
2009
25
7
Near Full-Length Genome
Characterization of an HIV-1 CRF01_AE
Strain in Jiangsu, China: Evidence of Two
Independent Introductions from Fujian
Dongmei Guo
Aids Research and
Human
Retroviruses - June
2009
25
6
Phylogenetic Analysis of HIV-1 Reverse
Transcriptase Sequences from 382
Patients Recruited in JJ Hospital of
Mumbai, India, between 2002 and 2008
Alaka Deshpande
Aids Research and
Human
Retroviruses - June
2009
25
6
Detection of Drug Resistance-Associated
and Background Mutations in Human
Immunodeficiency Virus Type 1
CRF01_AE Protease and Reverse
Transcriptase Derived from Drug
Treatment-Naive Patients Residing in
Central Thailand
Wattana Auwanit
Aids Research and
Human
Retroviruses - June
2009
25
6
Human Immunodeficiency Virus Type 1
gp 41 Mutations in Proviral DNA among
Antiretroviral Treatment-Naive Individuals
from India
Sourav Sen
Aids Research and
Human
Retroviruses - May
2009
25
5
A Novel Codon Insert in Protease of Clade
B HIV Type 1
Parris S. Jordan
Aids Research and
Human
Retroviruses - May
2009
25
5
Structural Basis of Drug Resistance by
Genetic Variants of HIV Type 1 Clade C
Protease from India
Abraham Joseph
Kandathil
Aids Research and
Human
Retroviruses - May
2009
25
5
Low Prevalence of Drug Resistance
Transmitted Virus in HIV Type 1-Infected
ARV-Naive Patients in Cambodia
Janin Nouhin
Aids Research and
Human
Retroviruses - May
2009
25
5
HIV Type 1 Drug Resistance in Adults
Receiving Highly Active Antiretroviral
Therapy in Abidjan, Côte d'Ivoire
Debra L. Hanson
Aids Research and
Human
Retroviruses - May
2009
25
5
High HIV Type 1 Prevalence and Wide
Genetic Diversity with Dominance of
Recombinant Strains But Low Level of
Antiretroviral Drug-Resistance Mutations
in Untreated Patients in Northeast Gabon,
Central Africa
Armel Mintsa-Ndong
Aids Research and
Human
Retroviruses April 2009
25
4
HIV Type 1 Group M Subtype G in
Cameroon: Five Genome Sequences
Julie Yamaguchi
Aids Research and
Human
Retroviruses April 2009
25
4
First Detection of a Novel HIV Type 1
CRF01_AE/07_BC Recombinant among
an Epidemiologically Linked Cohort of
IDUs in Jiangsu, China
Hongxiong Guo
Aids Research and
Human
Retroviruses April 2009
25
4
Effectiveness of antiretroviral therapy and
development of drug resistance in HIV-1
infected patients in Mombasa, Kenya.
Steegen K
AIDS Research
and Therapy - June
2009
6
12
HIV-1 Resistance to First- and SecondGeneration Non-nucleoside Reverse
Transcriptase Inhibitors
Jade Ghosn
AIDS Reviews
11
3
The Challenge of HIV-1 Antiretroviral
Resistance in Africa in the Era of HAART
Hakim Sendagire
AIDS Reviews
11
2
Characterization and Structural Analysis
of HIV-1 Integrase Conservation
Francesca CeccheriniSilberstein
AIDS Reviews
11
1
HIV-1 Genotypic Drug Resistance
Interpretation Rules – 2009 Spanish
Guidelines
Carmen de Mendoza
AIDS Reviews
11
1
Cohorts, trials, and evidence: expanding
our confidence in guidelines for
antiretroviral resistance testing.
Volberding P
Annals of Internal
Medicine - July
2009
151
2
Natural Polymorphisms of HIV-1 Integrase
and Inherent Susceptibilities to a Panel of
Integrase Inhibitors.
Low A
Antimicrobial
Agents and
Chemotherapy Epub ahead of
print
Use of different inhibitory quotients to
predict early virological response to
Tipranavir in antiretroviral experienced
HIV patients.
Morello J
Antimicrobial
Agents and
Chemotherapy Epub ahead of
print
Antiretroviral Drug Resistance
Surveillance among Treatment-Naive
Human Immunodeficiency Virus Type 1Infected Individuals in Angola: Evidence
for Low Level of Transmitted Drug
Resistance
Inês Bártolo
Antimicrobial
Agents and
Chemotherapy July 2009
53
7
Detection and Quantification of Minor
Human Immunodeficiency Virus Type 1
Variants Harboring K103N and Y181C
Resistance Mutations in Subtype A and D
Isolates by Allele-Specific Real-Time PCR
Andrea Hauser
Antimicrobial
Agents and
Chemotherapy July 2009
53
7
Protease Inhibitor Resistance Analysis in
the MONARK Trial Comparing First-Line
Lopinavir-Ritonavir Monotherapy to
Lopinavir-Ritonavir plus Zidovudine and
Lamivudine Triple Therapy
Constance Delaugerre
Antimicrobial
Agents and
Chemotherapy July 2009
53
7
Treatment with the Fusion Inhibitor
Enfuvirtide Influences the Appearance of
Mutations in the Human
Immunodeficiency Virus Type 1
Regulatory Protein Rev
Valentina Svicher
Antimicrobial
Agents and
Chemotherapy July 2009
53
7
Predictive Value of PharmacokineticsAdjusted Phenotypic Susceptibility on
Response to Ritonavir-Enhanced
Protease Inhibitors (PIs) in Human
Immunodeficiency Virus-Infected
Subjects Failing Prior PI Therapy
Joseph J. Eron Jr
Antimicrobial
Agents and
Chemotherapy June 2009
53
6
Susceptibility of Human
Immunodeficiency Virus Type 1 to the
Maturation Inhibitor Bevirimat Is
Modulated by Baseline Polymorphisms in
Gag Spacer Peptide 1
Kurt Van Baelen
Antimicrobial
Agents and
Chemotherapy May 2009
53
5
Human Immunodeficiency Virus Type 1
Isolates with the Reverse Transcriptase
(RT) Mutation Q145M Retain Nucleoside
and Nonnucleoside RT Inhibitor
Susceptibility
Vici Varghese
Antimicrobial
Agents and
Chemotherapy May 2009
53
5
Genotypic analysis of the protease and
reverse transcriptase of non-B HIV type 1
clinical isolates from naïve and treated
subjects.
Monno L
Antiviral Research
- Epub ahead of
print
Evolution of drug resistance after
virological failure of a first-line highly
active antiretroviral therapy regimen in
Uganda
Steven J Reynolds
Antiviral Therapy
14
4
HIV type-1 clade C resistance genotypes
in treatment-naive patients and after first
virological failure in a large community
antiretroviral therapy programme.
Orrell C
Antiviral Therapy
14
4
In vivo selection by enfuvirtide of HIV
type-1 env quasispecies with optimal
potential for phenotypic expression of
HR1 mutations.
Goubard A
Antiviral Therapy
14
Evolution and predictors of HIV type-1
drug resistance in patients failing
combination antiretroviral therapy in Italy
Simona Di
Giambenedetto
Antiviral Therapy
14
Resistance profiles after different periods
of exposure to a first-line antiretroviral
regimen in a Cameroonian cohort of HIV
type-1-infected patients
Alessandro Soria
Antiviral Therapy
14
Historical resistance profile helps to
predict salvage failure
Mauro Zaccarelli
Antiviral Therapy
14
Advantages of predicted phenotypes and
statistical learning models in inferring
virological response to antiretroviral
therapy from HIV genotype
André Altmann
Antiviral Therapy
14
Mutations in the thumb–connection and
RNase H domain of HIV type-1 reverse
transcriptase of antiretroviral treatmentexperienced patients
Joshua M Waters
Antiviral Therapy
14
Investigation of expert rule bases, logistic
regression, and non-linear machine
learning techniques for predicting
response to antiretroviral treatment
Mattia CF Prosperi
Antiviral Therapy
14
Immunological responses during a
virologically failing antiretroviral regimen
are associated with in vivo synonymous
mutation rates of HIV type-1 env
Helene Mens
Antiviral Therapy
14
Evaluation of transmitted HIV drug
resistance among recently-infected
antenatal clinic attendees in four Central
African countries
Martine Peeters
Antiviral Therapy
14
In vivo selection by enfuvirtide of HIV
type-1 env quasispecies with optimal
potential for phenotypic expression of
HR1 mutations
Béatrice Labrosse
Antiviral Therapy
14
HIV type-1 transmission dynamics in
recent seroconverters: relationship with
transmission of drug resistance and viral
diversity
Patricia RecordonPinson
Antiviral Therapy
14
A phylogenetic and Markov model
approach for the reconstruction of
mutational pathways of drug resistance.
Buendia P
Bioinformatics Epub ahead of
print
Virological efficacy and emergence of
drug resistance in adults on antiretroviral
Johannessen A
BMC Infectious
Diseases - July
9
4
108
treatment in rural Tanzania.
2009
Characterization of the patterns of drug
resistance mutations in newly diagnosed
HIV-1 infected patients naive to the
antiretroviral drugs.
Alteri C
BMC Infectious
Diseases - July
2009
9
1
High Frequency of Clinically Significant
Mutations after First-Line Generic Highly
Active Antiretroviral Therapy Failure:
Implications for Second-Line Options in
Resource-Limited Settings
N. Kumarasamy
Clinical Infectious
Diseases - July
2009
49
2
Antiretroviral Resistance Patterns and
HIV-1 Subtype in Mother-Infant Pairs after
the Administration of Combination ShortCourse Zidovudine plus Single-Dose
Nevirapine for the Prevention of Motherto-Child Transmission of HIV
Amphan
Clinical Infectious
Chalermchockcharoenkit Diseases - July
2009
49
2
High frequency of clinically significant
mutations after first-line generic highly
active antiretroviral therapy failure:
implications for second-line options in
resource-limited settings.
Kumarasamv N
Clinical Infectious
Diseases - July
2009
49
2
Replication Capacity of HIV-1 in the
Presence of Resistance-Associated
Substitutions in Protease
Dean L. Winslow
Clinical Infectious
Diseases - July
2009
49
1
High Frequency of Antiretroviral Drug
Resistance among HIV-Infected Adults
Receiving First-Line Highly Active
Antiretroviral Therapy in N’Djamena,
Chad
Donato Koyalta
Clinical Infectious
Diseases - July
2009
49
1
HIV-1 Superinfection in an HIV-2–Infected
Woman with Subsequent Control of HIV-1
Plasma Viremia
Huldrych F. Günthard
Clinical Infectious
Diseases - June
2009
48
11
Effect of HIV-1 Subtype on Virologic and
Immunologic Response to Starting Highly
Active Antiretroviral Therapy
Anna Maria Geretti
Clinical Infectious
Diseases - May
2009
48
9
Are All Subtypes Created Equal? The
Effectiveness of Antiretroviral Therapy
against Non–Subtype B HIV-1
Sergei L. Kosakovsky
Pond
Clinical Infectious
Diseases - May
2009
48
9
Low Levels of Antiretroviral-Resistant HIV
Infection in a Routine Clinic in Cameroon
that Uses the World Health Organization
(WHO) Public Health Approach to Monitor
Antiretroviral Treatment and Adequacy
with the WHO Recommendation for
Second-Line Treatment
Charles Kouanfack
Clinical Infectious
Diseases - May
2009
48
9
Clinical validation and applicability of
different tipranavir/ritonavir genotypic
scores in HIV-1 protease inhibitorexperienced patients.
Saracine A
Current HIV
Research - July
2009
7
4
Pre-screening HIV-1 reverse transcriptase
resistance mutations in subtype B
patients using a novel multiplex primer
extension assay.
Jakobsen MR
Current HIV
Research - July
2009
7
4
Management of paediatric HIV-1
resistance.
Gupta GB
Current Opinion
Infectious Diseases
- June 2009
22
3
Drug-resistant viruses may repair
impaired fitness by mutations outside the
drug target site.
Cai L
Future
Microbiology June 2009
4
507-9
Identification of new genotypic cut-off
levels to predict the efficacy of
lopinavir/ritonavir and darunavir/ritonavir
in the TITAN trial.
Hill A
HIV Medicine Epub ahead of
print
The mutational archive in proviral DNA
does not change during 24 months of
continuous or intermittent highly active
antiretroviral therapy
L Palmisano
HIV Medicine
10
8
Primary drug resistance and transmission
analysis of HIV-1 in acute and recent
drug-naïve seroconverters in Singapore
CC Lee
HIV Medicine
10
6
Prolonged use of tenofovir in
HIV/hepatitis B virus (HBV)-coinfected
individuals does not lead to HBV
polymerase mutations and is associated
with persistence of lamivudine HBV
polymerase mutations
J Audsley
HIV Medicine
10
4
Drug resistant mutations detected by
genotypic drug resistance testing in
patients failing therapy in clade C HIV-1
infected individuals from India.
Kandathil AJ
Indian Journal of
Medical
Microbiology July 2009
27
3
Effect of human immunodeficiency virus
type 1 protease inhibitor therapy and
subtype on development of resistance in
subtypes B and G.
Palma AC
Infections,
Genetics and
Evolution - Epub
ahead of print
The frequency of HIV-I drug resistance
mutations among treatment-naive
individuals at a tertiary care centre in
south India.
Kandathil AJ
International
20
Journal of STD and
AIDS - August
2009
8
Clinical and Genotypic Findings in HIVInfected Patients With the K65R Mutation
Failing First-Line Antiretroviral Therapy in
Nigeria.
Hawkins CA
JAIDS - Epub
ahead of print
Development of HIV-1 Drug Resistance
Through 144 Weeks in AntiretroviralNaïve Subjects on Emtricitabine,
Tenofovir Disoproxil Fumarate, and
Efavirenz Compared With
Lamivudine/Zidovudine and Efavirenz in
Study GS-01-934.
Margot NA
JAIDS - Epub
ahead of print
Lower Risk of Resistance After ShortCourse HAART Compared With
Zidovudine/Single-Dose Nevirapine Used
for Prevention of HIV-1 Mother-to-Child
Transmission
Lehman, Dara
JAIDS - August
2009
51
5
Molecular Epidemiological Study of HIV-1
CRF01_AE Transmission in Hong Kong
Chen, J H K
JAIDS - August
2009
51
5
Lower risk of resistance after shortcourse HAART compared with
zidovudine/single-dose nevirapine used
for prevention of HIV-1 mother-to-child
transmission.
Lehman DA
JAIDS - August
2009
51
5
Initiation of HAART at Higher CD4 Cell
Counts Is Associated With a Lower
Frequency of Antiretroviral Drug
Resistance Mutations at Virologic Failure
Uy, Jonathan
JAIDS - August
2009
51
4
HIV-1 Genetic Diversity and Transmitted
Drug Resistance in Health Care Settings
in Maputo, Mozambique
Bártolo, Inês MSc
JAIDS - July 2009
51
3
Increased Detection of HIV-1 Drug
Resistance at Time of Diagnosis by
Testing Viral DNA With a Sensitive Assay
Ellis, Giovanina M
JAIDS - July 2009
51
3
104 A V3-independent pathway to
resistance to small molecule CCR5
inhibitors
Anastasopoulou, Kleio
JAIDS - June 2009
51
2
Transmission Networks of Drug
Resistance Acquired in Primary/Early
Stage HIV Infection
BG, Brenner
JAIDS - June 2009
51
2
Survival of HIV-1 Infected MultidrugResistant Patients Recycling Enfuvirtide
After a Previous Failure
Cossarini, Francesca
JAIDS - June 2009
51
2
HIV-1 Transmission Cluster With T215D
Revertant Mutation Among Newly
Diagnosed Patients From the Basque
Country, Spain
Cuevas, Maria Teresa
JAIDS - May 2009
51
1
Lack of Primary Mutations Associated
With Integrase Inhibitors Among HIV-1
Subtypes B, C, and F Circulating in Brazil
Passaes, Caroline
Bittencourt
JAIDS - May 2009
51
1
Relationship of Injection Drug Use,
Antiretroviral Therapy Resistance, and
Genetic Diversity in the HIV-1 pol Gene
Kowalski, Jeanne
JAIDS - April
2009
50
4
Prevalence of transmitted HIV-1 drug
resistance in HIV-1-infected patients in
Italy: evolution over 12 years and
predictors
Bracciale L
Journal of
Antimicrobial
Chemotherapy Epub ahead of
print
Rules-based HIV-1 genotypic resistance
interpretation systems predict 8 week and
24 week virological antiretroviral
treatment outcome and benefit from drug
potency weighting.
Zazzi M
Journal of
Antimicrobial
Chemotherapy Epub ahead of
print
Fosamprenavir/ritonavir in advanced HIV
disease (TRIAD): a randomized study of
high-dose, dual-boosted or standard dose
fosamprenavir/ritonavir in HIV-1-infected
patients with antiretroviral resistance
Jean-Michel Molina
Journal of
Antimicrobial
Chemotherapy
64
2
HIV-1 reverse transcriptase thumb
subdomain polymorphisms associated
with virological failure to nucleoside drug
combinations
César Garriga
Journal of
Antimicrobial
Chemotherapy
64
2
Rapid selection and archiving of mutation
E157Q in HIV-1 DNA during short-term
low-level replication on a raltegravircontaining regimen
Jade Ghosn
Journal of
Antimicrobial
Chemotherapy
64
2
Using HIV resistance tests in clinical
practice
Stephen Taylor
Journal of
Antimicrobial
Chemotherapy
64
2
Evolution of raltegravir resistance during
therapy
Nadine Sichtig
Journal of
Antimicrobial
Chemotherapy
64
1
Rapid decline in the efficiency of HIV drug
resistance genotyping from dried blood
spots (DBS) and dried plasma spots
(DPS) stored at 37°C and high humidity
J. Gerardo GarcíaLerma
Journal of
Antimicrobial
Chemotherapy
64
1
Virological and immunological response
in HIV-1-infected patients with multiple
treatment failures receiving raltegravir
and optimized background therapy, ANRS
CO3 Aquitaine Cohort
Linda Wittkop
Journal of
Antimicrobial
Chemotherapy
63
6
Design and validation of new genotypic
tools for easy and reliable estimation of
HIV tropism before using CCR5
antagonists
Eva Poveda
Journal of
Antimicrobial
Chemotherapy
63
5
Quasispecies variant dynamics during
emergence of resistance to raltegravir in
HIV-1-infected patients
Isabelle Malet
Journal of
Antimicrobial
Chemotherapy
63
4
Novel recombinant virus assay for
measuring susceptibility of human
immunodeficiency virus type 1 group M
subtypes to clinically approved drugs.
Covens K
Journal of Clinical
Microbiology July 2009
47
7
Virological response to highly active
antiretroviral therapy in patients infected
with human immunodeficiency virus type
2 (HIV-2) and in patients dually infected
with HIV-1 and HIV-2 in the Gambia and
emergence of drug-resistant variants.
Jallows S
Journal of Clinical
Microbiology July 2009
47
7
Nevirapine Resistance in Human
Immunodeficiency Virus Type 1-Positive
Infants Determined Using Dried Blood
Spots Stored for Up to Six Years at Room
Temperature
Julie A. E. Nelson
Journal of Clinical
Microbiology April 2009
47
4
Mutation N155H in HIV-2 integrase
confers high phenotypic resistance to
raltegravir and impairs replication
capacity.
Salgado M
Journal of Clinical
Virology - Epub
ahead of print
Detection of the protease codon 35 amino
acid insertion in sequences from
treatment-naïve HIV-1 subtype C infected
individuals in the Central Region of
Portugal.
Pereira-Vaz J
Journal of Clinical
Virology - Epub
ahead of print
Mutation L33M in the HR1 region of HIV-1
gp41 may play a role in T20 resistance
Huihui Chong
Journal of Clinical
Virology - July
2009
45
3
Prevalence of minor variants of HIV
strains at reverse transcriptase position
103 in therapy-naïve patients and their
impact on the virological failure
Melanie Balduin
Journal of Clinical
Virology - May
2009
45
1
Resistance to antiretrovirals in HIVinfected pregnant women
Adriana Weinberg
Journal of Clinical
Virology - May
2009
45
1
Slow Accumulation of HIV Resistance
Mutations: Implications for ResourceLimited Settings?
Wendy S. Stevens
Journal of
Infectious Diseases
- September 2009
200
5
Rate of Accumulation of Thymidine
Analogue Mutations in Patients
Continuing to Receive Virologically
Failing Regimens Containing Zidovudine
or Stavudine: Implications for
Antiretroviral Therapy Programs in
Resource-Limited Settings
Alessandro Cozzi-Lepri
Journal of
Infectious Diseases
- September 2009
200
5
Failure of Treatment with First-Line
Lopinavir Boosted with Ritonavir Can Be
Explained by Novel Resistance Pathways
with Protease Mutation 76V
Monique Nijhuis
Journal of
Infectious Diseases
- September 2009
200
5
Predictive Value of HIV-1 Genotypic
Resistance Test Interpretation Algorithms
Soo-Yon Rhee
Journal of
Infectious Diseases
- August 2009
200
3
Establishment of Drug-Resistant HIV-1 in
Latent Reservoirs
Viktor Dahl
Journal of
Infectious Diseases
- May 2009
199
9
Identification of Nevirapine-Resistant HIV1 in the Latent Reservoir after SingleDose Nevirapine to Prevent Mother-toChild Transmission of HIV-1
Megan Wind-Rotolo
Journal of
Infectious Diseases
- May 2009
199
9
Circulating HIV Type 1 Drug Resistance
Will Have Limited Impact on the
Effectiveness of Preexposure Prophylaxis
among Young Women in Zimbabwe
David A. M. C. van de
Vijver
Journal of
Infectious Diseases
- May 2009
199
9
Antiretroviral Drug Resistance in HIV-2:
Three Amino Acid Changes Are Sufficient
for Classwide Nucleoside Analogue
Resistance
Robert A. Smith
Journal of
Infectious Diseases
- May 2009
199
9
Prevalence of the K65R resistance
reverse transcriptase mutation in different
HIV-1 subtypes in Israel
Dan Turner
Journal of Medical
Virology
81
9
The relationship between genotypic
sensitivity score and treatment outcomes
in late stage HIV disease after supervised
HAART
Delivette Castor
Journal of Medical
Virology
81
8
Absence of genotypic drug resistance
and presence of several naturally
occurring polymorphisms of human
immunodeficiency virus-1 CRF06_cpx in
treatment-naive patients in Estonia
Radko Avi
Journal of Medical
Virology
81
6
Evaluation of Different RNA Extraction
Methods and Storage Conditions of Dried
Plasma or Blood Spots for Human
Immunodeficiency Virus Type 1 RNA
Quantification and PCR Amplification for
Drug Resistance Testing
Marjorie Monleau
Journal of Medical
Virology - April
2009
47
4
Differences in resistance mutations
among HIV-1 non-subtype B infections: a
systematic review of evidence (19962008).
Martinez-Cajas JL
Journal of the
International AIDS
Society - June
2009
12
1
Sensitive detection of the K103N nonnucleoside reverse transcriptase inhibitor
resistance mutation in treatment-naïve
HIV-1 infected individuals by rolling circle
amplification.
Wang B
Journal of
Virological
Methods - October
2009
161
1
Clinical Cut-offs for HIV-1 Phenotypic
Resistance Estimates: Update Based on
Recent Pivotal Clinical Trial Data and a
Revised Approach to Viral Mixtures.
Winters B
Journal of
Virological
Methods - Epub
ahead of print
Gag Determinants of Fitness and Drug
Susceptibility in Protease Inhibitor
Resistant HIV-1.
Parry CM
Journal of Virology
- Epub ahead of
print
Selective advantage profile of HIV-1
integrase mutants explain in vivo
evolution of raltegravir resistance
genotypes.
Quercia R
Journal of Virology
- Epub ahead of
print
The impact of individual HIV-1 protease
mutations on drug susceptibility is highly
influenced by complex interactions with
the background protease sequence.
Van Marck H
Journal of Virology
- Epub ahead of
print
Molecular characterization of clinical
isolates of human immunodeficiency
virus resistant to the protease inhibitor
darunavir.
Saskova KG
Journal of Virology 83
- September 2009
17
Positive selection pressure introduces
secondary mutations at gag cleavage
sites in human immunodeficiency virus
type 1 harboring major protease
resistance mutations.
Banke S
Journal of Virology 83
- September 2009
17
Subtype-Specific Differences in the
Human Immunodeficiency Virus Type 1
Reverse Transcriptase Connection
Subdomain of CRF01_AE Are Associated
with Higher Levels of Resistance to 3'Azido-3'-Deoxythymidine.
Delviks-Frankenberry
KA
Journal of Virology 83
- September 2009
17
Tissue-Specific Sequence Alterations in
the Human Immunodeficiency Virus Type
1 Envelope Favoring CCR5 Usage
Contribute to Persistence of Dual-Tropic
Virus in the Brain
Lachlan Gray
Journal of Virology 83
- June 2009
11
Impact of Human Immunodeficiency Virus
Type 1 Resistance to Protease Inhibitors
on Evolution of Resistance to the
Maturation Inhibitor Bevirimat (PA-457)
Catherine S. Adamson
Journal of Virology 83
- May 2009
10
Replicative Capacity Differences of
Thymidine Analog Resistance Mutations
in Subtype B and C Human
Immunodeficiency Virus Type 1
Kimberly L. Armstrong
Journal of Virology 83
- May 2009
9
Predictors of Virologic Failure and
Genotypic Resistance Mutation Patterns
in Thai Children Receiving NonNucleoside Reverse Transcriptase
Inhibitor-Based Antiretroviral Therapy.
Jittamala P
Paediatric
Infectious Diseases
- Epub ahead of
print
Low-abundance HIV drug-resistant viral
variants in treatment-experienced
persons correlate with historical
antiretroviral use.
Le T
PLoS One - June
2009
4
6
HIV transmission in a state prison
system, 1988-2005.
Jafa K
PLoS One - May
2009
4
5
Quantitative deep sequencing reveals
dynamic HIV-1 escape and large
population shifts during CCR5 antagonist
therapy in vivo.
Tsibris AM
PLoS One - May
2009
4
5
Virological monitoring and resistance to
first-line highly active antiretroviral
therapy in adults infected with HIV-1
treated under WHO guidelines: a
systematic review and meta-analysis
Ravindra K Gupta
The Lancet
Infectious Diseases
- July 2009
9
7